For decades, the U.S. life sciences industry has been centered around a handful of established innovation hubs. Boston, San Diego, the San Francisco Bay Area, and North Carolina’s Research Triangle Park have long attracted the industry’s leading companies, investors, and scientific talent.
But today’s biotechnology landscape is changing. Rising operating costs, increased competition for talent, and limited manufacturing capacity are prompting companies to reevaluate where they build, grow, and commercialize new therapies. Rather than concentrating solely on traditional coastal hubs, many organizations are looking toward emerging regions with the right combination of talent, infrastructure, investment, and long-term growth potential.
One such region quietly and steadily gaining momentum is Oklahoma City. After years of strategic investment and ecosystem building, Oklahoma City is now seeing that work translate into a thriving life sciences community, and that progress is gaining national attention. Through sustained investment, collaborative leadership, and an expanding workforce network, the region has been highlighted in a recent look at emerging biotech markets as one of three areas to watch, pointing to Oklahoma City’s growing attraction for companies developing the next generation of biologic therapies.
Building an Ecosystem Takes More Than Just Great Science
A successful life sciences hub is not built around a single breakthrough or one major institution. It requires multiple interconnected elements working together. That includes world-class research institutions, a highly skilled workforce, experienced entrepreneurs, manufacturing and laboratory infrastructure, access to local and national capital investment, and a culture of collaboration between industry, academia, and government.
Oklahoma City has been steadily strengthening each of these building blocks simultaneously. Rather than relying on one strength, the region has focused on creating an environment designed to help companies launch, grow, and scale throughout every stage of development. This coordinated approach is helping develop an ecosystem where scientific innovation can more easily move from discovery to commercialization without companies needing to leave the state.
A Workforce Built for Long-term Growth
One of Oklahoma City’s greatest competitive advantages is its workforce. Many life sciences professionals who have grown up, studied, or built careers in the Midwest share a culture rooted in collaboration, long-term career growth, and community. These values translate into stronger employee retention, lower turnover, and greater continuity across organizations.
For companies operating in highly regulated industries like biologics manufacturing, workforce stability provides meaningful operational advantages. Experienced employees preserve institutional knowledge, maintain quality standards, and strengthen long-term operational consistency. Cytovance has experienced these benefits firsthand, with many team members remaining with the organization for more than a decade. As Morgan Bates, DSP Manufacturing Manager at Cytovance, explains:
“The values that are uniquely Oklahoman are that we take pride in the work that we put out and the quality of that work. We are happy to share knowledge and educate others. And we’re always happy to collaborate for the best possible results.”
At the same time, Oklahoma continues investing in education and workforce development initiatives through university partnerships and specialized training programs, such as the University of Oklahoma (OU) Bioprocessing Core Facility, that prepare the next generation of life sciences professionals. Together, these efforts provide companies with a reliable talent pipeline capable of supporting sustained growth as they scale.
Investment is Accelerating Growth
Strong life sciences ecosystems require more than talent; they also require capital. Oklahoma City’s continued growth is being fueled by a combination of private investment, public funding, and strategic economic development initiatives.
Companies throughout the region are benefiting from increasing venture capital interest, angel investors, state incentive programs, and federal funding opportunities that support both workforce and infrastructure development. Public-private partnerships have also played an important role in helping companies establish new operations and expand existing capabilities.
What makes Oklahoma City’s investment landscape particularly compelling is the diversity of available funding sources. Rather than relying on a single avenue or a single region for financial support, companies can leverage multiple investment channels that support innovation from early-stage research through commercialization. As Craig Shimasaki, Ph D, Co-Founder, President, and CEO of Moleculera Biosciences, an OKC precision medicine company, shared:
“In the center of the country, it’s not like Silicon Valley or Boston. Your money goes a lot farther because of the cost of living, the cost of the facilities; all of those things are more manageable. There’s a lot of capital available. And even though Oklahoma has a strong investment culture, 90% of the capital I raised has actually come from out of state. In fact, we have people who have invested three, four, five times into our development-stage company.”
Infrastructure is Reaching Critical Mass
As Oklahoma City’s life sciences community continues to expand, so too does the infrastructure supporting it. Today, companies increasingly have access to the scientific, manufacturing, and testing resources needed to advance discoveries toward commercialization without leaving Oklahoma.
The region’s growing network includes nationally recognized organizations such as the Oklahoma Medical Research Foundation, the University of Oklahoma, the Stephenson Cancer Center, and an expanding base of CDMOs, analytical testing providers, and workforce training centers. Together, these organizations create an integrated ecosystem that supports innovation from early discovery through development, manufacturing, and clinical advancement.
The ability to access these capabilities locally helps reduce barriers to commercialization while encouraging companies to keep innovation and manufacturing activities within the region.
Oklahoma City is Reaching an Inflection Point
The momentum behind Oklahoma City’s life sciences sector comes at an important time for the broader U.S. biopharmaceutical industry. As companies look to strengthen supply chain resilience and reduce reliance on overseas manufacturing, demand for domestic development and manufacturing capacity is growing. With this renewed focus on U.S.-based manufacturing, regions with established scientific talent and infrastructure have an opportunity to play a larger role in supporting the next generation of therapies.
Oklahoma City is positioned to meet that need. More biotechnology companies are choosing to establish operations in the region, while experienced industry leaders are relocating to help shape its future, and continued investment from both the public and private sectors strengthens the ecosystem year after year. Additionally, organizations such as Life Science Oklahoma are helping connect industry, academia, government, and investors through advocacy, networking, workforce initiatives, and industry events that foster collaboration across the community.
As demand for domestic biomanufacturing grows, that combination of expertise, capabilities, and collaboration can help position the region as a valuable part of the U.S. life sciences landscape. Rather than trying to replicate traditional established biotech hubs, Oklahoma City is developing its own collaborative model built on accessibility, partnership, and sustainable long-term growth.
Looking Ahead
Strong life sciences ecosystems are built over time through collaboration, investment, talent development, and infrastructure expansion. Oklahoma City now possesses many of the essential ingredients needed to compete on a national scale.
As Oklahoma’s first CDMO, Cytovance is proud to be part of this continued growth. By expanding biomanufacturing capabilities and supporting innovators developing the next generation of biologic therapies, the company is helping strengthen Oklahoma City’s position as an emerging life sciences destination. Jeffrey Seymore, President and CEO of the Oklahoma City Innovation District, put it best when he shared that:
“The Cytovance story is an Oklahoma City story. From the beginning, its founders believed, long before it was popular, that you could build a world-class bioscience company right here in Oklahoma. As Cytovance continues to grow and evolve, so does Oklahoma City.”
As more companies seek locations that offer scientific excellence, operational advantages, long-term growth potential, and access to domestic development and manufacturing capabilities, Oklahoma City is increasingly demonstrating that the future of life sciences innovation is not limited to the coasts. It is being built in communities that prioritize collaboration, invest in their people, and create the conditions for companies to thrive.
—